3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
2
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
7
Pancreatic Neoplasms
6
Brain Neoplasms
6
Neoplasms
5
Glioma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Liver Neoplasms
2
Glioblastoma
2
Disease
2
Central Nervous System Neoplasms
2
Astrocytoma
2
Urinary Bladder Neoplasms
1
Soft Tissue Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Penile Neoplasms
1
Pediatric Brain Tumor
1
Pancreatic Cyst
1
Osteosarcoma
1
Nervous System Diseases
1
Muscle Weakness
1
Metabolic Diseases
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
6
pembrolizumab
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
Drug Therapy
4
fludarabine
3
XELOX
3
Specimen Handling
3
Laparoscopy
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
Magnetic Resonance Imaging
×
Clear all
NCT04103372
2024-11-04
PRESERVE
Imperial College London
Phase NA
Recruiting
200 enrolled